GENELINK ANNOUNCES PUBLICATION OF ITS PATENT APPLICATION RELATING TO METHODS OF ASSESSING OXIDATIVE STRESS
October 22, 2002

MARGATE, NJ - (Business Wire) - October 22, 2002- GeneLink BioSciences, Inc. (OTCBB:GNLK) announced today that on October 10, 2002, the U.S. Patent & Trademark Office formally published the first of GeneLink's patent applications relating to methods of assessing oxidative stress by analyzing genetic polymorphisms. Filed on April 5, 2002, U.S. Patent Application No. 09/826,522 can be reviewed by entering publication number 20020146698 at the following World Wide Web URL: 

http://appft1.uspto.gov/netahtml/PTO/srchnum.html and entering the number: 20020146698 

GeneLink has three (3) additional Patent Applications pending in the U.S. Patent & Trademark Office relating to methods of assessing Bone Density, Cardiovascular and Skin Health by analyzing genetic polymorphisms. These applications are scheduled to be published within the next 24 months. GeneLink is licensing these proprietary assessments to companies that manufacture or market to the $100 Billion plus personal care, nutritional supplement and skin care industries. These profile assessments are tools to help companies create and deliver more effective products - personalized wellness and 'quality of life' products tailored to their customer's individual needs - based on the science of genetics. Consumers will no longer be forced to guess what nutritional supplements or skin care products are best for their specific needs. 

For the first time, simply by swabbing the inside of the mouth with GeneLink's patented DNA Collection Kit®, consumers can now enjoy the benefits of a tailored nutritional or skin care regimen designed to their individual needs. For more information about GeneLink, visit its website at www.genelink.info. 

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.